"Waan ku faraxsanahay inaan u soo bandhigno CEQUA sidii doorasho cusub oo daaweyn ah oo loogu talagalay in ka badan lix milyan oo Kanadiyaanka ah ee la nool cudurrada indhaha ee qallalan1," ayuu yiri Abhay Gandhi, Maamulaha Waqooyiga Ameerika, Sun Pharma. "Daah-furkaani waa guul muhiim u ah Sun Pharma maadaama aan ballaarinayno faylalka indhaha ee Kanada waxayna muujineysaa sida ay nooga go'an tahay bixinta dawooyin cusub oo lagu taageerayo doorashada bukaanka iyo dhakhtarka."
Marka lagu daro baahsanaantii hore ee dadka Kanadiyaanka ah, warbixin dhowaan ka soo baxday Xarunta Cilmi-baarista & Waxbarashada Indhaha (CORE) ayaa muujisay in heerarka cudurrada indhaha ee qallalan ay kor u kacayaan sababtoo ah kor u kaca xirashada maaskaro, taas oo keeni karta dhibco qallalan. oogada indhaha.2
"Waxaan ku faraxsanahay inaan aragno badeeco cusub oo hadda ay heli karaan dad badan oo Kanadiyaanka ah oo la ildaran keratoconjunctivitis sicca ama cudurrada indhaha qallalan," ayuu yiri W. Bruce Jackson, MD, Professor hore iyo Guddoomiyaha, Waaxda Ophthalmology, Jaamacadda McGill iyo Jaamacadda Ottawa. "CEQUA, oo leh tignoolajiyadeeda nanomicellar iyo xoogga korodhka ee cyclosporine, waxay noqon kartaa wax dheeraad ah oo muhiim ah oo ku saabsan doorashooyinkayaga daawaynta iyada oo xirfadlayaasha daryeelka indhaha ay ku dadaalayaan daaweyn gaar ah."
